| 2023 |
| 12/04 | 15:05 臨時株主総会招集のための基準日設定及び臨時株主総会招集ならびに資本金の額の減少に関するお知らせ |
| 12/01 | 25 | 25 | 23 | 23 | -8% | 6,956,500 | 50億580万 | -11.54% |
| 11/30 | 25 | 26 | 25 | 25 | 0% | 7,246,000 | 54億4109万 | -7.41% |
| 11/29 | 25 | 26 | 25 | 25 | 0% | 2,207,800 | 54億4109万 | -7.41% |
| 11/28 | 26 | 27 | 25 | 25 | -3.85% | 2,487,400 | 54億4109万 | -7.41% |
| 11/27 | 27 | 27 | 26 | 26 | 0% | 3,314,900 | 56億5873万 | -3.7% |
| 11/24 | 26 | 27 | 25 | 26 | +4% | 4,063,600 | 56億5873万 | -3.7% |
| 11/22 | 26 | 27 | 25 | 25 | -3.85% | 2,629,900 | 54億4109万 | -7.41% |
| 11/21 | 25 | 28 | 25 | 26 | 0% | 5,166,300 | 56億5873万 | -3.7% |
| 11/20 | 25 | 26 | 25 | 26 | 0% | 4,749,400 | 56億5873万 | -7.14% |
| 11/17 | 25 | 26 | 24 | 26 | 0% | 4,539,300 | 56億5873万 | -7.14% |
| 11/16 | 26 | 27 | 25 | 26 | 0% | 3,548,700 | 56億5873万 | -7.14% |
| 11/15 | 26 | 27 | 25 | 26 | 0% | 3,042,000 | 56億5873万 | -7.14% |
| 11/14 | 26 | 27 | 25 | 26 | -3.7% | 2,796,900 | 56億5873万 | -7.14% |
| 11/13 | 27 | 28 | 26 | 27 | -3.57% | 2,703,400 | 58億7637万 | -3.57% |
| 11/10 | 17:00 2024年3月期第2四半期決算短信〔日本基準〕(連結) |
| 11/10 | 28 | 28 | 27 | 28 | 0% | 8,504,700 | 60億9402万 | 0% |
| 11/09 | 29 | 29 | 27 | 28 | 0% | 2,720,400 | 60億9402万 | 0% |
| 11/08 | 27 | 29 | 26 | 28 | +7.69% | 7,184,200 | 60億9402万 | 0% |
| 11/07 | 27 | 27 | 26 | 26 | 0% | 3,041,300 | 56億5873万 | -10.34% |
| 11/06 | 26 | 27 | 25 | 26 | 0% | 2,969,500 | 56億5873万 | -10.34% |
| 11/02 | 26 | 27 | 26 | 26 | 0% | 1,968,800 | 56億5873万 | -10.34% |
| 11/01 | 27 | 27 | 26 | 26 | -3.7% | 1,675,800 | 56億5873万 | -10.34% |
| 10/31 | 28 | 28 | 26 | 27 | -3.57% | 5,823,200 | 58億7637万 | -6.9% |
| 10/30 | 28 | 29 | 28 | 28 | 0% | 2,966,200 | 60億9402万 | -6.67% |
| 10/27 | 29 | 29 | 28 | 28 | -3.45% | 5,787,600 | 60億9402万 | -6.67% |
| 10/26 | 15:30 第三者割当による第35回新株予約権(行使価額修正条項付)の行使価額修正に関するお知らせ |
| 10/26 | 29 | 30 | 28 | 29 | -3.33% | 6,931,700 | 63億1166万 | -3.33% |
| 10/25 | 29 | 30 | 29 | 30 | +7.14% | 6,058,700 | 65億2931万 | 0% |
| 10/25 | 8:30 AMED「日本医療研究開発機構革新的がん医療実用化研究事業」への、徳島大学研究プロジェクト(研究開発分担者)の採択について |
| 10/24 | 28 | 29 | 28 | 28 | -3.45% | 5,742,100 | 60億9402万 | -6.67% |
| 10/23 | 28 | 29 | 28 | 29 | 0% | 5,516,600 | 63億1166万 | -3.33% |
| 10/20 | 29 | 29 | 28 | 29 | 0% | 3,013,100 | 63億1166万 | -3.33% |
| 10/19 | 28 | 29 | 28 | 29 | 0% | 3,430,400 | 63億1166万 | -3.33% |
| 10/18 | 29 | 29 | 28 | 29 | 0% | 2,900,700 | 63億1166万 | -3.33% |
| 10/17 | 30 | 30 | 28 | 29 | -6.45% | 3,872,200 | 63億1166万 | -3.33% |
| 10/16 | 29 | 31 | 28 | 31 | +3.33% | 2,606,300 | 67億4695万 | +3.33% |
| 10/13 | 29 | 30 | 29 | 30 | 0% | 3,453,900 | 65億2931万 | 0% |
| 10/12 | 29 | 30 | 28 | 30 | 0% | 2,821,600 | 65億2931万 | 0% |
| 10/11 | 29 | 30 | 28 | 30 | 0% | 4,153,700 | 65億2931万 | 0% |
| 10/10 | 29 | 30 | 28 | 30 | +7.14% | 2,307,900 | 65億2931万 | 0% |
| 10/06 | 29 | 29 | 28 | 28 | -3.45% | 1,616,400 | 60億9402万 | -6.67% |
| 10/05 | 28 | 29 | 28 | 29 | +3.57% | 1,567,700 | 63億1166万 | -3.33% |
| 10/04 | 28 | 29 | 28 | 28 | -3.45% | 2,020,900 | 60億9402万 | -9.68% |
| 10/03 | 30 | 30 | 28 | 29 | -6.45% | 5,185,900 | 63億1166万 | -6.45% |
| 10/02 | 31 | 31 | 30 | 31 | -3.13% | 2,455,400 | 67億4695万 | 0% |
| 10/02 | 8:30 当社連結子会社における、HIVE CLX Single-cell RNAseq Solutionを用いたシングルセルRNAシーケンス解析受託開始のお知らせ |
| 09/29 | 32 | 32 | 31 | 32 | 0% | 1,569,100 | 69億6459万 | +3.23% |
| 09/28 | 31 | 33 | 31 | 32 | +3.23% | 1,890,900 | 69億6459万 | +3.23% |
| 09/27 | 31 | 32 | 31 | 31 | 0% | 910,100 | 67億4695万 | 0% |
| 09/26 | 31 | 32 | 30 | 31 | 0% | 2,937,700 | 67億4695万 | +3.33% |
| 09/25 | 30 | 31 | 30 | 31 | 0% | 896,500 | 67億4695万 | +3.33% |
| 09/22 | 30 | 31 | 30 | 31 | 0% | 991,100 | 67億4695万 | +3.33% |
| 09/21 | 31 | 31 | 30 | 31 | 0% | 1,158,900 | 67億4695万 | +3.33% |
| 09/20 | 30 | 31 | 30 | 31 | +3.33% | 1,619,500 | 67億4695万 | +3.33% |
| 09/19 | 31 | 31 | 30 | 30 | 0% | 1,201,400 | 65億2931万 | 0% |
| 09/15 | 31 | 32 | 30 | 30 | -3.23% | 3,198,100 | 65億2931万 | 0% |
| 09/14 | 30 | 31 | 30 | 31 | +3.33% | 1,255,500 | 67億4695万 | +3.33% |
| 09/13 | 30 | 31 | 30 | 30 | 0% | 1,542,600 | 65億2931万 | 0% |
| 09/12 | 31 | 31 | 30 | 30 | 0% | 1,056,300 | 65億2931万 | 0% |
| 09/12 | 8:30 当社連結子会社のDroplet Digital PCRシンポジウム2023におけるリキッドバイオプシーに関する講演発表のお知らせ |
| 09/11 | 30 | 31 | 30 | 30 | -3.23% | 1,398,400 | 65億2931万 | 0% |
| 09/08 | 31 | 31 | 30 | 31 | +3.33% | 1,113,700 | 67億4695万 | +3.33% |
| 09/07 | 30 | 31 | 30 | 30 | 0% | 1,354,400 | 65億2931万 | 0% |
| 09/06 | 31 | 31 | 30 | 30 | 0% | 1,565,100 | 65億2931万 | 0% |
| 09/05 | 30 | 31 | 30 | 30 | -3.23% | 1,246,900 | 65億2931万 | -3.23% |
| 09/04 | 30 | 31 | 30 | 31 | 0% | 1,167,600 | 67億4695万 | 0% |
| 09/01 | 31 | 32 | 30 | 31 | 0% | 2,975,600 | 67億4695万 | 0% |
| 08/31 | 31 | 32 | 31 | 31 | 0% | 1,055,000 | 67億4695万 | 0% |
| 08/30 | 31 | 32 | 30 | 31 | +3.33% | 1,859,700 | 67億4695万 | 0% |
| 08/29 | 31 | 32 | 30 | 30 | -3.23% | 1,700,700 | 65億2931万 | -3.23% |
| 08/28 | 31 | 32 | 30 | 31 | 0% | 1,784,600 | 67億4695万 | 0% |
| 08/25 | 30 | 31 | 29 | 31 | +3.33% | 1,893,200 | 67億4695万 | 0% |
| 08/24 | 31 | 31 | 29 | 30 | 0% | 2,121,300 | 65億2931万 | -3.23% |
| 08/23 | 30 | 31 | 29 | 30 | +3.45% | 3,277,300 | 65億2931万 | -3.23% |
| 08/22 | 29 | 30 | 29 | 29 | 0% | 2,534,000 | 63億1166万 | -9.38% |
| 08/21 | 28 | 29 | 28 | 29 | +3.57% | 3,204,100 | 59億9266万 | -9.38% |
| 08/18 | 28 | 29 | 28 | 28 | 0% | 2,991,800 | 57億8602万 | -12.5% |
| 08/17 | 29 | 29 | 28 | 28 | -3.45% | 2,151,800 | 57億8602万 | -12.5% |
| 08/16 | 29 | 30 | 28 | 29 | -3.33% | 4,061,400 | 59億9266万 | -12.12% |
| 08/15 | 31 | 32 | 28 | 30 | -3.23% | 7,695,500 | 61億9931万 | -9.09% |
| 08/14 | 32 | 33 | 31 | 31 | 0% | 2,181,700 | 64億595万 | -6.06% |
| 08/10 | 17:00 営業外費用の発生に関するお知らせ |
| 08/10 | 17:00 2024年3月期第1四半期決算短信〔日本基準〕(連結) |
| 08/10 | 31 | 33 | 31 | 31 | -3.13% | 3,042,900 | 64億595万 | -8.82% |
| 08/09 | 32 | 32 | 31 | 32 | 0% | 1,570,200 | 66億1259万 | -5.88% |
| 08/08 | 32 | 34 | 31 | 32 | +3.23% | 5,376,600 | 66億1259万 | -5.88% |
| 08/07 | 31 | 32 | 31 | 31 | -3.13% | 1,673,700 | 64億595万 | -11.43% |
| 08/04 | 31 | 32 | 31 | 32 | +3.23% | 3,152,800 | 66億1259万 | -8.57% |
| 08/04 | 8:30 新規化合物に関する共同研究契約締結のお知らせ |
| 08/03 | 32 | 33 | 31 | 31 | -6.06% | 4,344,200 | 64億595万 | -11.43% |
| 08/02 | 33 | 34 | 32 | 33 | 0% | 4,237,600 | 68億1924万 | -8.33% |
| 08/01 | 15:00 第三者割当による第34回新株予約権(行使価額修正条項付)の月間行使状況及び行使完了に関するお知らせ |
| 08/01 | 34 | 35 | 33 | 33 | -2.94% | 2,456,300 | 68億1924万 | -8.33% |
| 07/31 | 34 | 35 | 33 | 34 | +3.03% | 3,536,000 | 70億2588万 | -8.11% |
| 07/28 | 32 | 34 | 32 | 33 | 0% | 2,873,000 | 68億1924万 | -10.81% |
| 07/27 | 31 | 34 | 31 | 33 | +6.45% | 5,513,900 | 68億1924万 | -10.81% |
| 07/26 | 17:00 第三者割当による第34回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ |
| 07/26 | 31 | 32 | 30 | 31 | -3.13% | 5,613,500 | 64億595万 | -18.42% |
| 07/25 | 32 | 33 | 31 | 32 | -3.03% | 6,450,300 | 66億1259万 | -15.79% |
| 07/24 | 32 | 33 | 31 | 33 | +3.13% | 3,707,600 | 68億1924万 | -15.38% |
| 07/21 | 34 | 34 | 32 | 32 | -3.03% | 8,250,500 | 66億1259万 | -17.95% |
| 07/20 | 34 | 35 | 33 | 33 | -2.94% | 6,304,300 | 68億1924万 | -17.5% |
| 07/19 | 35 | 36 | 34 | 34 | -2.86% | 5,793,900 | 70億2588万 | -15% |
| 07/18 | 35 | 37 | 35 | 35 | -5.41% | 4,088,600 | 72億3252万 | -12.5% |
| 07/14 | 35 | 37 | 35 | 37 | +2.78% | 4,623,000 | 76億4581万 | -7.5% |
| 07/13 | 36 | 37 | 35 | 36 | 0% | 4,502,000 | 74億3917万 | -12.2% |
| 07/12 | 36 | 38 | 36 | 36 | 0% | 3,660,800 | 74億3917万 | -12.2% |
| 07/11 | 37 | 38 | 36 | 36 | 0% | 3,794,500 | 74億3917万 | -12.2% |
| 07/10 | 38 | 39 | 36 | 36 | -5.26% | 4,117,600 | 74億3917万 | -12.2% |
| 07/07 | 38 | 39 | 37 | 38 | -2.56% | 3,545,300 | 78億5246万 | -7.32% |
| 06/30 | 17:00 公益財団法人財務会計基準機構への加入状況及び加入に関する考え方等に関するお知らせ |
| 06/30 | 17:00 事業計画及び成長可能性に関する事項 |
